<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872352</url>
  </required_header>
  <id_info>
    <org_study_id>Version 1.1</org_study_id>
    <nct_id>NCT00872352</nct_id>
  </id_info>
  <brief_title>Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients</brief_title>
  <official_title>Phase 3 Study to Evaluate Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the present study we are planning to study electrophysiological changes related to the
      dose and time of bortezomib administration in newly diagnosed patients with MM, during the
      first months of treatment and 6 months after ending. In addition a possible correlation
      between the incidence of BIPN and the subtype of myeloma and other risk factors will be
      investigated.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>April 2009</start_date>
  <completion_date type="Anticipated">August 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A dose-related neurotoxic effect of bortezomib will be determined through regression analysis with the change in TNSr as the dependent variable Bortezomib doses will use as independent variables.</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To accommodate the dose of bortezomib with the progression of Peripheral Neuropathy</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Peripheral Neuropathy</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>EMG</intervention_name>
    <description>Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age&gt; 18

          -  Patients with Multiple Myeloma stage II, III (Durie and Salmon staging) prior to
             Bortezomib Therapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status â‰¤ 2

          -  Be willing and able to comply with the protocol treatment for the duration of the
             study

          -  Patient's written informed consent

        Exclusion Criteria:

          -  Multiple Myeloma on progression

          -  Incidence of Relapsed or Refractory Myeloma

          -  Patients with the existing neuropathy at the time of the diagnosis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eliezer Rachmilewitz, MD</last_name>
    <role>Study Director</role>
    <affiliation>Head of Hematology, Wolfson MC, Holon, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Husam Ghoti, MD</last_name>
    <phone>972-35028778</phone>
    <email>drghoti123@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wolfson MC</name>
      <address>
        <city>Holon</city>
        <zip>58100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Husam Ghoti, MD</last_name>
      <phone>972-5028778</phone>
      <email>drghoti123@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>March 30, 2009</last_update_submitted>
  <last_update_submitted_qc>March 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>HusamGhoti, MD</name_title>
    <organization>Hematology Dept., Wolfson MC</organization>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Bortezomib</keyword>
  <keyword>Peripheral Neuropathy</keyword>
  <keyword>evaluation</keyword>
  <keyword>evaluation of electrophysiological changes related to the dose and time of bortezomib administration</keyword>
  <keyword>investigation of correlation between the incidence of BIPN and the subtype of myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

